← Back to Search

Genetic Test

Genetic Testing for Acute Coronary Syndrome (ACCURATE Trial)

N/A

Recruiting

Led By Liam Brunham, MD PhD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Admitted to an acute cardiac unit with either a ST elevation myocardial infarction (STEMI) or a non-ST elevation myocardial infarction (NSTEMI)

Maximum lipid level at the time of admission or during the prior 1 year of: LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, Non-HDL-C ≥4.6 mmol/L (177 mg/dL) if LDL-C not available

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and improve patient care and outcomes.

Who is the study for?

This trial is for people under 60 who've been admitted to a cardiac unit with a heart attack (STEMI or NSTEMI) and have high cholesterol levels. It's not open to those already diagnosed with Familial Hypercholesterolemia or on certain lipid treatments.

What is being tested?

The ACCURATE study tests if genetic testing for Familial Hypercholesterolemia in patients hospitalized for acute coronary syndrome can help diagnose this condition and influence their treatment and health outcomes.

What are the potential side effects?

Since the intervention involves genetic testing, there are no direct physical side effects. However, receiving genetic information may have psychological impacts or affect insurance status.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was admitted for a heart attack.

Select...

My cholesterol levels have been high in the past year.

Select...

I am younger than 60 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Proportion of patients who achieve guideline recommended lipid targets in the first year after ACS

Other study objectives

Rate of recurrent cardiovascular event in the first year after ACS

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active-testingExperimental Treatment1 Intervention

Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.

Group II: ObservationActive Control1 Intervention

Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.

0 / 3Eligibility criteria met